Sanofi Stock Other OTC
Stocks
SNYNF
FR0000120578
Pharmaceuticals
OTC Markets Traded
| Market Cap | 87B 99.57B 80.48B 75.12B 141B 9,409B 142B 956B 372B 4,626B 374B 366B 16,071B | P/E 2026 * |
10.8x | P/E 2027 * | 10.1x |
|---|---|---|---|---|---|
| Enterprise Value | 97.81B 112B 90.47B 84.44B 159B 10,578B 160B 1,075B 418B 5,201B 420B 411B 18,067B | EV / Sales 2026 * |
2.08x | EV / Sales 2027 * | 1.9x |
| Free-Float |
89% | Yield 2026 * |
5.87% | Yield 2027 * | 6.22% |
Last Transcript: Sanofi
| 1 day | -1.88% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2026-04-30 | |
| Director of Finance/CFO | 64 | 2024-03-31 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 2023-09-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 2019-04-29 | |
Rachel Duan
BRD | Director/Board Member | 56 | 2020-04-27 |
Lise Kingo
BRD | Director/Board Member | 64 | 2020-04-27 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.88% | -.--% | - | - | 99.57B | |
| +0.32% | -2.41% | +44.49% | +140.80% | 983B | |
| +1.27% | -1.85% | +54.41% | +39.65% | 557B | |
| +6.25% | +3.80% | +24.13% | +67.39% | 406B | |
| +1.22% | -1.93% | +23.33% | +16.35% | 314B | |
| +1.17% | +1.63% | +29.56% | +18.19% | 273B | |
| +1.38% | +2.14% | +28.59% | +34.81% | 272B | |
| +0.43% | +8.62% | -32.44% | -44.06% | 203B | |
| +2.11% | -1.66% | +19.14% | +50.10% | 186B | |
| +0.90% | +0.46% | +15.09% | +59.86% | 155B | |
| Average | +1.37% | -0.92% | +22.92% | +42.57% | 372.26B | |
| Weighted average by Cap. | +1.51% | -2.22% | +31.74% | +64.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.07B 53.87B 43.54B 40.64B 76.29B 5,090B 76.84B 517B 201B 2,503B 202B 198B 8,694B | 49.98B 57.2B 46.23B 43.15B 81.01B 5,405B 81.6B 549B 214B 2,658B 215B 210B 9,232B |
| Net income | 8.15B 9.32B 7.53B 7.03B 13.2B 881B 13.3B 89.53B 34.84B 433B 35B 34.24B 1,505B | 8.95B 10.25B 8.28B 7.73B 14.51B 968B 14.62B 98.43B 38.3B 476B 38.48B 37.64B 1,654B |
| Net Debt | 10.8B 12.36B 9.99B 9.33B 17.51B 1,168B 17.64B 119B 46.2B 574B 46.42B 45.41B 1,996B | 8.08B 9.25B 7.48B 6.98B 13.1B 874B 13.2B 88.85B 34.57B 430B 34.73B 33.98B 1,493B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
